Do you consider adjuvant chemotherapy for older women >75 years of age, with HR+ invasive ductal carcinoma and 3 positive LN however intermediate risk recurrence scores?

Until the prospective data from RxPONDER is out, we only have retrospective data for node + disease. Based on the Israeli Registry study, 2-3+ node patients with scores under 18 had a 5-year recurrence rate of 5.4%. For N+ patients, the recurrences were lower for chemo vs no chemo (1% vs 9.7%) in th...